MedTrace Logo

Outpatient Registry Trial of Respiratory Tract Infections in Adults

NCT00245453 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2015-07-28

No results posted yet for this study

Summary

To measure the speed of bacterial eradication from the respiratory tract after administration of azithromycin or telithromycin.

Conditions

  • Pneumonia, Bacterial
  • Bronchitis, Chronic

Interventions

DRUG

azithromycin

250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5

DRUG

telithromycin

400 mg tablets; 2 tablets once daily (QD) for 5 days

DRUG

Clarythromycin

500 mg extended release tablets; 2 tablets QD for 7 days

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • CPL Associates

    lead OTHER

Principal Investigators

  • Jerome J Schentag, Pharm.D. · State University of New York at Buffalo

  • Joseph Paladino, Pharm.D. · State University of New York at Buffalo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Completion
2006-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00245453 on ClinicalTrials.gov